CaMKII-dependent SR Ca leak contributes to doxorubicin-induced impaired Ca handling in isolated cardiac myocytes

Journal of Molecular and Cellular Cardiology

Volumn 51, Issue 5, 2011, Pages 749-759

  Sag, Can M ^a   Köhler, Anne C ^a   Anderson, Mark E ^b   Backs, Johannes ^c   Maier, Lars S ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Calcium cycling excitation contraction coupling; Calcium calmodulin dependent protein kinase II; Cell signalling signal transduction; Oxidant stress; SR calcium leak

Indexed keywords

CALCIUM; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA; DOXORUBICIN; ISOENZYME; MELATONIN; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CARDIOTOXICITY; CELL ISOLATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENZYME METABOLISM; ENZYME PHOSPHORYLATION; ENZYME SPECIFICITY; EPIFLUORESCENCE MICROSCOPY; HEART MUSCLE CELL; HEART VENTRICLE OVERLOAD; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SARCOPLASMIC RETICULUM; WESTERN BLOTTING; WILD TYPE;

ACTION POTENTIALS; ANIMALS; BENZYLAMINES; BLOTTING, WESTERN; CALCIUM; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; DIASTOLE; DOXORUBICIN; FREE RADICAL SCAVENGERS; GENE EXPRESSION; ION TRANSPORT; ISOENZYMES; MELATONIN; MICE; MICROSCOPY, FLUORESCENCE; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; SARCOPLASMIC RETICULUM; SULFONAMIDES;

RATTUS;

EID: 80053259051     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2011.07.016     Document Type: Article

References (43)

1. Yeh E.T.H., Bickford C.L. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009, 53:2231-2247.
2. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004, 56:185-229.
3. Weiss R.B. The anthracyclines: will we ever find a better doxorubicin?. Semin Oncol 1992, 19:670-686.
4. Zuppinger C., Timolati F., Suter T. Pathophysiology and diagnosis of cancer drug induced cardiomyopathy. Cardiovas Toxicol 2007, 7:61-66.
5. Wouters K.A., Kremer L.C., Miller T.L., Herman E.H., Lipshultz S.E. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 2005, 131:561-578.
6. Krischer J.P., Epstein S., Cuthbertson D.D., Goorin A.M., Epstein M.L., Lipshultz S.E. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol 1997, 15:1544-1552.
7. Lipshultz S.E., Colan S.D., Gelber R.D., Perez-Atayde A.R., Sallan S.E., Sanders S.P. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991, 324:808-815.
8. Mulrooney D.A., Yeazel M.W., Kawashima T., Mertens A.C., Mitby P., Stovall M., et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009, 339:b4606.
9. Abramson J.J., Buck E., Salama G., Casida J.E., Pessah I.N. Mechanism of anthraquinone-induced calcium release from skeletal muscle sarcoplasmic reticulum. J Biol Chem 1988, 263:18750-18758.
10. Timolati F., Ott D., Pentassuglia L., Giraud M.N., Perriard J.C., Suter T.M., et al. Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes. J Mol Cell Cardiol 2006, 41:845-854.
11. 2+ increase are reciprocally modulated in rat cardiomyocytes. Exp Mol Med 2006, 38:535-545.
12. Torkaska-Schlattner M., Zaugg M., Zuppinger C., Wallimann T., Schlattner U. New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol 2006, 41:389-405.
13. Vásquez-Vivar J., Martasek P., Hogg N., Masters B.S.S., Pritchard K.A., Kalyanaraman B. Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochem 1997, 36:11293-11297.
14. Thannickal V.J., Fanburg B.L. Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol 2000, 279:1005-1028.
15. Zima A.V., Blatter L.A. Redox regulation of cardiac calcium channels and transporters. Cardiovasc Res 2006, 71:310-321.
16. Seddon M., Looi Y.H., Shah A.M. Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. Heart 2007, 93:903-907.
17. 2+ leak in chronic heart failure. Circ Res 2008, 103:1466-1472.
18. Xu L., Eu J.P., Meisser G., Stamler J.S. Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation. Science 1998, 279:234-237.
19. 2+ exchange in ventricular myocytes. Am J Physiol 1996, 271:823-833.
20. Goldhaber J.I., Liu E. Excitation-contraction coupling in single guinea-pig ventricular myocytes exposed to hydrogen peroxide. J Physiol 1994, 477:135-147.
21. Erickson J.R., Joiner M.A., Guan X., Kutschke W., Yang J., Oddis C.V., et al. A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell 2008, 133:462-474.
22. 2+/calmodulin-dependent protein kinase (CaMK) in excitation-contraction coupling in the heart. Cardiovasc Res 2007, 73:631-640.
23. Koval O.M., Guan X., Wu Y., Joiner M.L., Gao Z., Chen B., et al. CaV1.2 beta-subunit coordinates CaMKII-triggered cardiomyocyte death and afterdepolarizations. Proc Natl Acad Sci U S A 2010, 107:4996-5000.
24. 2+ release. Circ Res 2003, 92:904-911.
25. 2+/calmodulin-dependent protein kinase II improves contractility in human failing myocardium. Circ Res 2010, 107:1150-1161.
26. Backs J., Backs T., Neef S., Kreusser M.M., Lehmann L.H., Patrick D.M., et al. The delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload. Proc Natl Acad Sci U S A 2009, 106:2342-2347.
27. Sag C.M., Dybkova N., Neef S., Maier L.S. Effects on recovery during acidosis in cardiac myocytes overexpressing CaMKII. J Mol Cell Cardiol 2007, 43:696-709.
28. Sag C.M., Wadsack D.P., Khabbazzadeh S., Abesser M., Grefe C., Neumann K., et al. Calcium/calmodulin-dependent protein kinase II contributes to cardiac arrhythmogenesis in heart failure. Circ Heart Fail 2009, 2:664-675.
29. Bers D.M. Excitation-contraction coupling and cardiac contractile force 2001, Kluwer Academic Press, Dordrecht, The Netherlands. 2nd ed.
30. Reiter R.J., Tan D.X., Cabrera J., D'Arpa D. Melatonin and tryptophan derivatives as free radical scavengers and antioxidants. Adv Exp Med Biol 1999, 467:379-387.
31. Gao L., Blair L.A., Marshall J. CaMKII-independent effects of KN93 and its inactive analog KN92: reversible inhibition of L-type calcium channels. Biochem Biophys Res Commun 2006, 345:1606-1610.
32. 2+-content in isolated rat and rabbit myocardium. J Mol Cell Cardiol 2000, 32:2249-2258.
33. 2+ transport. Circ Res 2003, 93:487-490.
34. 2+ leak in intact ventricular myocytes from rabbits in heart failure. Circ Res 2003, 93:592-594.
35. Kohlhaas M., Zhang T., Seidler T., Zibrova D., Dybkova N., Steen A., et al. Increased sarcoplasmic reticulum calcium leak but unaltered contractility by acute CaMKII overexpression in isolated rabbit cardiac myocytes. Circ Res 2006, 98:235-244.
36. + channels. J Clin Invest 2006, 116:3127-3138.
37. 2+ leak in heart failure. Circ Res 2005, 97:1314-1322.
38. Khoo M.S., Li J., Singh M.V., Yang Y., Kannankeril P., Wu Y., et al. Death, cardiac dysfunction, and arrhythmias are increased by calmodulin kinase II in calcineurin cardiomyopathy. Circulation 2006, 114:1352-1359.
39. Zhang R., Khoo M.S., Wu Y., Yang Y., Grueter C.E., Ni G., et al. Calmodulin kinase II inhibition protects against structural heart disease. Nat Med 2005, 11:409-417.
40. Toischer K., Rokita A.G., Unsöld B., Zhu W., Kararigas G., Sossalla S., et al. Differential cardiac remodeling in preload versus afterload. Circulation 2010, 122:993-1003.
41. Ganame J., Claus P., Eyskens B., Uyttebroeck A., Renard M., D'hooge J., et al. Acute cardiac functional and morphological changes after anthracycline infusions in children. Am J Cardiol 2007, 99:974-977.
42. Eschenhagen T., Force T., Ewer M.S., de Keulenaer G.W., Suter T.M., Anker S.D., et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2011, 13:1-10.
43. Bleyer W.A. The impact of childhood cancer on the United States and the world. CA Cancer J Clin 1990, 40:355-367.